References
- Ackland S P., Schilsky R L. High-dose methotrexate: A critical reappraisal. J Clin Oncol. 1987; 5: 2017–2031
- Jaffe N. Disturbances induced by high-dose methotrexate treatment. Cancer. 1985; 56: 1356–1360
- Walker R W., Allen J C., Rosen G, Caparros B. Transient neurological dysfunction secondary to high-dose methotrexate. J Clin Oncol. 1986; 4: 1845–1850
- Schornagel J H., McVie J G. The clinical pharmacology of methotrexate. Cancer Treat Rev. 1983; 10: 53–75
- Henze G, Fengler R, Hartmann R. Six year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL-REZ BFM 85). A relapse study of the BFM group. Blood. 1991; 78: 1166–1172
- Zaccara G, Messori A, Moroni F. Clinical pharmacokinetics of valproic acid—1988. Clin Phar-macokinet. 1988; 15: 367–389
- Dickinson R G., Hooper W D., Dunstan P R., Eadie M J. Urinary excretion of valproate and some metabolites in chronically treated patients. Ther Drug Monit. 1989; 11: 127–133
- Winick N J., Bowman W P., Kamen B A. Unexpected acute neurologic toxicity in the treatment of children with acute lymphoblastic leukemia. J Natl Cancer Inst. 1992; 84: 252–256
- Dimario FJ, Jr., Packer R J. Acute mental status changes in children with systemic cancer. Pediatrics. 1990; 85: 353–360
- Ochs J J., Bowman W P., Pui C H. Seizures in childhood acute lymphoblastic leukemia patients. Lancet. 1984; 2: 1422–1424